Day: March 4, 2020

Bekaert lost ambities margeverbetering en afbouw werkkapitaal en schuldgraad inOnderliggende EBIT stijgt met 15% tot € 242 miljoen – werkkapitaal daalt met 20% – nettoschuld/onderliggende EBITDA van 2.1Bekaert heeft de uitdagende marktomstandigheden (door handelsspanningen, politieke en –beleidswijzigingen, en sociale protesten die wereldwijd economieën hebben geaffecteerd) geneutraliseerd en heeft resultaat afgeleverd op alle gestelde prioriteiten om de balans te herstellen en de margeperformantie te verbeteren.Kerncijfers boekjaar 2019Geconsolideerde omzet van € 4,3 miljard (+0,4%) en gezamenlijke omzet van € 5,1 miljard (+1,1%)Onderliggende EBIT van € 242 miljoen, een stijging met 15% en resulterend in een marge van 5,6%Onderliggende EBITDA van € 468 miljoen (+10%) aan een dubbelcijferige marge op omzet (10,8%)Onderliggende ROCE van...

Bekaert répond aux priorités établies en matière de marges, de fonds de roulement et de désendettementEBIT sous-jacent en hausse de 15% à € 242 millions – fonds de roulement en baisse de 20% – endettement net/EBITDA sous-jacent de 2,1Bekaert a réussi à compenser les conditions de marché difficiles causées par des tensions et barrières commerciales, des changements politiques ainsi que des protestations sociales affectant les économies à l’échelle mondiale et a donné suite à toutes les priorités établies visant à rétablir un bilan sain et à améliorer la performance des marges.Faits marquants financiers 2019Chiffre consolidé de € 4,3 milliards (+0,4%) et chiffre global de € 5,1 milliards (+1,1%)EBIT sous-jacent de € 242 millions, en hausse de 15% par rapport à 2018 et représentant une marge de 5,6%EBITDA sous-jacent de € 468...

Very satisfying 2019 annual resultsRecord organic growth, solid EBITDA margin, significant increase of headline net result and free cash-flowVery good Group financial performance in 2019Record revenue: €3,281.8mn (+4.7% of which +3.3% organic growth)EBITDA margin at 33.6% of revenue (31.5% excluding IFRS 16 impact, flat vs 2018)Headline net result of €256mn (€260mn excluding IFRS 16 impact, i.e. +16% vs 2018)Free cash-flow of €247mn (€186mn excluding IFRS 16 impact, i.e. +21% vs 2018)Improvement of leverage ratio at 3.2x as of 31 December 2019Operational achievements in all geographies, reflecting the relevance of Elis’ strategySatisfactory price increases in all countries subject to high inflation of their cost baseVery good commercial momentum in France, Southern Europe, Latin America and Scandinavia & Eastern Europe, mainly due...

 Résultats annuels 2019 très satisfaisantsCroissance organique record, solidité de la marge d’EBITDA, augmentation significative du résultat net courant et du free cash-flowTrès bonne performance financière du Groupe en 2019Chiffre d’affaires record à 3 281,8m€ (+4,7% dont +3,3% de croissance organique)Marge d’EBITDA à 33,6% du chiffre d’affaires (31,5% en excluant l’impact IFRS16, stable vs 2018)Résultat net courant de 256m€ (260m€ en excluant l’impact IFRS16, soit +16% vs 2018)Free cash-flow de 247m€ (186m€ en excluant l’impact IFRS 16, soit +21% vs 2018)Amélioration du levier d’endettement à 3,2x au 31 décembre 2019Succès opérationnels dans toutes les zones géographiques, reflétant la pertinence de la stratégie d’ElisHausses de prix satisfaisantes dans les pays sujets à une forte inflation de leur base de coûtsTrès bonne dynamique...

Amsterdam, 4 March 2020 – Arcadis (EURONEXT: ARCAD), the leading global Design & Consultancy organization for natural and built assets, today announced the resignation of Sarah Kuijlaars, Chief Financial Officer (CFO) and Member of the Executive Board, effective 4 March 2020.Sarah Kuijlaars, who joined Arcadis as CFO in April 2018, is leaving Arcadis for personal reasons and in mutual agreement. Consequently, the Supervisory Board will initiate the process to appoint a new CFO for the next stage of Arcadis’ development.“We thank Sarah for her contribution to Arcadis in the past two years. Under her financial leadership we created a strong balance sheet and a solid financial foundation for future growth”, said Peter Oosterveer, CEO and Chairman of the Executive Board.Niek Hoek, Chairman of the Supervisory Board,...

The Elecsys GALAD score aims to support clinicians in diagnosing hepatocellular carcinoma by giving them more timely and accurate information to make earlier interventionsWhen hepatocellular carcinoma is detected and managed at the very earliest, patient’s 5-year survival rates can increase to over 70%1Utilizing blood-based biomarkers, as part of the Elecsys GALAD score, is minimally invasive to patientsBasel, 4 March 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to the Elecsys® GALAD score.* This algorithmic score combines gender and age with the biomarker results of the Elecsys AFP, AFP-L3 and PIVKA-II and is intended to aid diagnosis of early stage hepatocellular carcinoma (HCC).The Elecsys GALAD score will be the first GALAD...

Marketing Authorization Application (MAA) based on data from the head-to-head OPTIMUM Phase 3 study, presented at the 35th Congress of The European Committee for Treatment and Research in Multiple SclerosisIdorsia Pharmaceuticals Ltd and Actelion Pharmaceuticals Ltd, a member of the Janssen Pharmaceutical Companies of Johnson & Johnson, have a revenue-sharing agreement in respect to ponesimodAllschwil, Switzerland – March 4, 2020Idorsia Ltd (SIX: IDIA) today informed that the Janssen Pharmaceutical Companies of Johnson & Johnson announced the submission of a MAA to the European Medicines Agency (EMA) seeking approval for ponesimod for the treatment of adult patients with relapsing multiple sclerosis (MS).For further details please read the full announcement available here:https://johnsonandjohnson.gcs-web.com/static-files/8444902a-4913-4258-bb4c-7d60f9db257fAbout...

Marketing Authorization Application (MAA) based on data from the head-to-head OPTIMUM Phase 3 study, presented at the 35th Congress of The European Committee for Treatment and Research in Multiple SclerosisIdorsia Pharmaceuticals Ltd and Actelion Pharmaceuticals Ltd, a member of the Janssen Pharmaceutical Companies of Johnson & Johnson, have a revenue-sharing agreement in respect to ponesimodAllschwil, Switzerland – March 4, 2020Idorsia Ltd (SIX: IDIA) today informed that the Janssen Pharmaceutical Companies of Johnson & Johnson announced the submission of a MAA to the European Medicines Agency (EMA) seeking approval for ponesimod for the treatment of adult patients with relapsing multiple sclerosis (MS).For further details please read the full announcement available here:https://johnsonandjohnson.gcs-web.com/static-files/8444902a-4913-4258-bb4c-7d60f9db257fAbout...

Hoivatilat PlcStock Exchange Release 4 March 2020 at 8:00 a.m. EETHoivatilat Plc has published its Annual Report 2019Hoivatilat has published its Annual Report 2019 at https://hoivatilat.fi/en/for-investors/reports-and-presentations/. The Annual Report is also attached to this release in PDF format.The Annual Report 2019 contains the Report of the Board of Directors, Group Financial Statements, Auditor’s Report Hoivatilat’s Corporate Governance Statement.Further information:Riikka SäkkinenHR and Communications Managertel. +358 40 524 2768Hoivatilat in brief:Hoivatilat Plc specialises in producing, developing, owning and leasing out nursing homes, day care centres, schools and service communities. Founded in 2008, the company has been working in cooperation with as many as 60 Finnish municipalities and has launched 200 property...

SAN JOSE, Calif., March 03, 2020 (GLOBE NEWSWIRE) — Zoom Video Communications, Inc. (NASDAQ:ZM) today announced general availability of its Zoom Phone cloud phone service in 11 additional countries (Total 17 countries and one territory now) and Beta Service in 24 new countries and one territory.Zoom Phone now supports local phone numbers and PSTN access with new Metered and Unlimited Calling Plans in Austria, Belgium, Denmark, France, Germany, Italy, Netherlands, Portugal, Spain, Sweden, and Switzerland. This expanded geographic coverage allows Zoom customers all over the world to migrate away from their in-country legacy phone systems to consolidate business communications into Zoom’s all-in-one, video-first unified communications platform.Zoom Phone Beta Service will also be available to existing qualified Zoom customers upon...